A multinational conglomerate in the biopharmaceutical sector, specializing in manufacturing life-saving medical formulations for diabetes and cardiovascular conditions. The organization handles critical data daily - including classified research and sensitive patient information - making it a target for cyber criminals, and it sought to enhance its IT and security infrastructure to strengthen its cybersecurity posture.
The biopharmaceutical industry faces growing cybersecurity threats amid digital transformation, relying heavily on digital technologies that create vulnerabilities to operational disruption, data breaches, financial loss and reputational damage. Being cash-rich with sensitive patient data and intellectual property, pharmaceutical organizations attract ransomware actors who send malicious attachments that encrypt files and demand payment for decryption keys. The organization recognized an urgent need to enhance its IT and security infrastructure, specifically by deploying an Endpoint Detection and Response (EDR) solution strategically across the enterprise.